Andrew James
Managing Director & CEO
Andrew is a co-founder of iClinix, and has been with the Company since
inception. He has a wealth of experience in health based technologies and
pharmaceutical and eHealth business development. At Mayne Pharma, he initiated
and managed the development of one of the largest business development programs
seen in the Australian hospital sector. This program focused on the highly
specialised and complex pharmaceuticals market. Andrew also worked as a
consultant at IBM (from 1992 to 1996) as The National Health Programme Manager,
and has overseen and project managed many very successful deployments of
clinical applications into major hospitals. Andrew has headed up iClinix since
its inception and led the project teams that were a precursor to the founding
of iClinix since early 2000. He was instrumental in the design, development and
commercialization of the National Clozapine monitoring database and the
National Cerebral Palsy Register.
For the last ten years, Andrew has worked on the development of specialized
clinical software projects and has actively participated in the Standards
Australia electronic health initiatives (IT014). Andrew is also an elected
executive of the Australian Information Industry Association NSW management
team and is Deputy Chair of that Executive Group. In addition to this industry
commitment, he Chairs the AIIA Health ICT Sector Special Interest Group. He has
a B.Ec from Sydney University and a range of additional university awards as
well having lectured at the University of Western Sydney in 1996 in the
Department of Computing Science and Communications. He has also specialized in
managing and motivating sales and account management teams in the
pharmaceutical and biotechnology sector.
Gerard Chanekon
Executive Director & CIO/CTO
Gérard is a co-founder of iClinix and has been the technical leader of the
Company since its inception. He has spent the past twenty years working on
high-tech computer software. His ability to decipher complex problems and
turning them into functional and elegant solutions and his strong technical
leadership are the corner stones on which iClinix is built.
He had previously worked as a senior solutions architect, project manager and
senior technical consultant for organisations such as Macquarie Bank, Ord
Minnett, PriceWaterhouseCoopers, Telstra Bigpond, Woolworths Limited, Ok Tedi
Mining. He has also worked for Electricité De France and France Telecom
designing and implementing critical software systems to help improve
efficiencies, safety and accuracy.
Gérard has a Post Graduate Diploma in Computer Science obtained in France at the
prestigious University Of Toulouse (third largest university in France and one
of the oldest in Europe founded in 1229) situated in the famous technology
centre of Toulouse, home to the CNES’s Toulouse Space Centre, Galileo
positioning system and Airbus.
In recent years, Gérard has become an expert in n-Tier based technology and has
led teams to the successful construction and implementation of very
comprehensive clinical systems and clinical registries such as Transnet or the
National Cerebral Palsy Register.
Dr Ian Gardner
Medical Advisor
Ian is a qualified specialist medical doctor who was the Medical Director for
IBM Asia Pacific from mid the 1980s through to 1998. He has extensive networks
of high-level acquaintances in the Government and private sector, as well as
having gained a Master in Public health (Sydney University), focusing on
bio-information and statistics. Ian has been a Board Advisor since mid 2006,
and has agreed to take on a directorship for a minimum of two years commencing
in May 2007.
Ian has a wealth of experience in health based ICT systems as well as an
intimate knowledge of specialist doctor requirements. He will play an active
role in guiding the company’s medical liaison strategy, and assisting at a
director to director level with key pharmaceutical clients and state and
national Health Departments.
Roy Brown
Chief Financial Officer
Roy gained extensive experience working in the UK in corporate finance after
having qualified as a chartered accountant at Arthur Andersen in 1995. He
recently spent two years working as Chief Financial Officer and Company
Secretary for an ASX listed biotechnology company, and took that company
through its ASX listing process as CFO. He has also worked for multi-national
pharmaceutical companies in the United Kingdom, and is currently assisting
Johnson & Johnson on a contractual basis with the Pfizer merger
integration. Roy will provide considerable expertise and experience in guiding
iClinix through its capital raising programs, as well as significant input into
the medium and long-terms business and financial strategies and plans of the
Company.
Dr Douglas Campbell
Chief Scientific Officer
Douglas Campbell is an experienced Biotechnology Product Development
Specialist. He has extensive experience working with clinical data to test
emerging products as well as to search for new candidate products or new
indications for existing high cost drugs. Douglas is also a shareholder of
iClinix and has developed an expertise in reviewing and validating clinical
systems.
Dr Renee Badenhop
Biotechnology & Information
Technology Advisor
Renee has advanced qualification in human genetics, biostatistic linkage
analysis, as well as being a qualified Patent Attorney specialising in
biotechnology products and services. Renees Medical Doctorate was followed by
Post Doctoral projects at the prestigious Garvan Instutute based in Sydney
Australia. This inlcuded programs at the University of Zurich and Rockafella
University.
